Rhythm Pharmaceuticals annonce l’approbation par Santé Canada de IMCIVREE® setmélanotide pour…
<!-- Name:DistributionId Value:8834057 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
PCSK1
Rhythm Pharmaceuticals annonce l’autorisation par la Commission européenne de…
BOSTON, 27 juill. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial qui s'est engagée à transformer les soins apportés aux personnes atteintes de formes génétiques…
Rhythm Pharmaceuticals gibt Zulassung der Europäischen Kommission für IMCIVREE® (Setmelanotid)▼ für…
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich dem Ziel verschrieben hat, die Behandlung von Menschen mit seltenen, genetisch…
Rhythm Pharmaceuticals anuncia la autorización de la Comisión Europea de IMCIVREE® (setmelanotida)▼…
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), empresa biofarmacéutica en fase comercial comprometida con la transformación del cuidado de las personas que viven con enfermedades genéticas raras de…
Rhythm Pharmaceuticals annuncia l’autorizzazione da parte della Commissione europea di…
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale impegnata a cambiare radicalmente l'assistenza delle persone affette da malattie genetiche rare…
Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for…
BOSTON, July 23, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today…
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and…
BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced…